Want to see OSG full AI Analyst Report?
Top Page
Octave Specialty Group
(NYSE:OSG)
Select Model
Select Model
Rating:50Neutral
Price Target:
$5.50
â–²(10.66% Upside)
Action:Reiterated
Date:08/07/26
Overall score reflects a tug-of-war between improving operating momentum and raised segment guidance (supportive) versus still-weak fundamentals—large GAAP losses, negative margins, and negative operating/free cash flow (dominant risk). Technicals are mildly bearish and valuation is difficult to anchor due to negative earnings, keeping the score near the middle of the range.
Positive Factors
Insurance Distribution Growth
Rapid organic growth and higher segment guidance indicate strong demand, successful integration of ArmadaCare, and expanding distribution capacity. Sustained growth in this segment can improve the company’s mix and provide a more scalable earnings foundation.
Negative Factors
Persistent GAAP Losses and Negative Margins
Despite better adjusted results, deep GAAP losses and negative operating margins indicate that the business has not yet converted growth into durable reported profitability. This limits earnings quality and leaves performance sensitive to expenses and adjustments.
Read all positive and negative factors
Positive Factors
Negative Factors
Insurance Distribution Growth
Rapid organic growth and higher segment guidance indicate strong demand, successful integration of ArmadaCare, and expanding distribution capacity. Sustained growth in this segment can improve the company’s mix and provide a more scalable earnings foundation.
Read all positive factors
Octave Specialty Group (OSG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$223.91M
Dividend Yield1.9%
Average Volume (3M)509.98K
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue Growth7.99%
EPS Growth-698.73%
CountryUS
Employees483
SectorFinancial
Sector Strength70
IndustryInsurance - Specialty
Share Statistics
EPS (TTM)-3.64
Shares Outstanding45,051,487
10 Day Avg. Volume591,643
30 Day Avg. Volume509,983
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.51
Price to Sales (P/S)1.46
P/FCF Ratio-7.02
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.50Price Target Upside131.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.19
Revenue Forecast (FY)$87.97M
Octave Specialty Group Business Overview & Revenue Model
Company Description
Octave Specialty Group, Inc. functions as a financial services holding company, organizing its operations into two distinct divisions. Its Specialty Property and Casualty Insurance segment delivers specialized program insurance, primarily focusing...
How the Company Makes Money
null...
Octave Specialty Group Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Positive
The call emphasized strong and accelerating performance in the Insurance Distribution segment (77% revenue growth, 44% organic), material quarter-over-quarter improvements in consolidated and segment profitability, meaningful underwriting progress at Everspan (loss ratio and combined ratio improvements), and operational initiatives (AI, talent hires) that support scalable growth. At the same time, the company remains GAAP unprofitable, reduced its adjusted EPS and Everspan EBITDA guidance for near-term items (acquisition/onboarding costs), faces a softening P&C market in certain property classes, and is making near-term investments (MGAs, technology) that depress current margins. On balance, operational momentum and improving adjusted results outweigh the near-term headwinds and guidance adjustments.Positive Updates
Insurance Distribution Revenue and Organic Growth
Insurance Distribution revenue grew 77% year-over-year to $58.4 million in Q2 2026, driven by 44% organic growth and the October 2025 acquisition of ArmadaCare.
Negative Updates
GAAP Net Loss Persists
Octave reported a GAAP net loss to shareholders of $14.4 million ($0.33 per share) in Q2 2026, so while improving materially, the company remains net-loss-making on a GAAP basis this quarter.
Read all updates
Q2-2026 Updates
Positive
Negative
Insurance Distribution Revenue and Organic Growth
Insurance Distribution revenue grew 77% year-over-year to $58.4 million in Q2 2026, driven by 44% organic growth and the October 2025 acquisition of ArmadaCare.
Read all positive updates
Company Guidance
Management updated 2026 guidance, raising Insurance Distribution organic growth to 25%+ (from 20%+) and increasing Insurance Distribution adjusted EBITDA guidance to $45M (from $40M) — reflecting Q2 momentum (Insurance Distribution Q2 revenue +77%, Q2 organic growth 44%, Q2 adjusted EBITDA ≈$10M and YTD adjusted EBITDA $35M with an approx. 26% margin). Everspan’s adjusted EBITDA guidance was lowered to $6M (from $7.5M), which would still represent a ~58% increase over 2025’s $3.8M adjusted EBITDA, due to higher near-term acquisition costs. Consolidated adjusted net income per share guidance was revised to $0.15–$0.20 (vs. prior $0.50), with the midpoint implying roughly a $0.76 per-share improvement from 2025’s adjusted loss of $0.58; management reiterated 2026 is expected to be the first year of positive adjusted net income per share (ex-legacy financial guarantee business) since the P&C strategy launch.Octave Specialty Group Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
63
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 320.67M | 251.22M | 235.81M | 124.73M | 53.61M | 247.00M |
| Gross Profit | 266.86M | 204.03M | 98.65M | 47.99M | 24.36M | 319.00M |
| EBITDA | -17.96M | -40.42M | -30.52M | -18.99M | -31.91M | 246.00M |
| Net Income | -141.06M | -240.92M | -556.45M | 3.63M | 521.25M | -17.00M |
Balance Sheet | ||||||
| Total Assets | 1.64B | 2.22B | 8.06B | 8.43B | 7.97B | 12.30B |
| Cash, Cash Equivalents and Short-Term Investments | 213.24M | 337.18M | 331.90M | 354.96M | 1.93B | 1.85B |
| Total Debt | 155.46M | 117.56M | 150.00M | 3.48B | 3.75B | 6.45B |
| Total Liabilities | 621.59M | 1.14B | 6.86B | 7.00B | 6.65B | 11.19B |
| Stockholders Equity | 698.75M | 715.79M | 856.91M | 1.36B | 1.25B | 1.04B |
Cash Flow | ||||||
| Free Cash Flow | -62.13M | -52.28M | 762.00K | 200.00M | 70.37M | -131.00M |
| Operating Cash Flow | -62.13M | -52.28M | 762.00K | 200.00M | 70.37M | -131.00M |
| Investing Cash Flow | 229.92M | 199.94M | -166.37M | 435.00M | -41.16M | 776.00M |
| Financing Cash Flow | -132.95M | -126.30M | 194.22M | -423.00M | -19.23M | -657.00M |
Octave Specialty Group Technical Analysis
Negative
4.97
Price Trends
5.54
Negative
5.32
Negative
6.01
Negative
Market Momentum
-0.29
Negative
39.30
Neutral
36.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSG, the sentiment is Negative. The current price of 4.97 is above the 20-day moving average (MA) of 4.83, below the 50-day MA of 5.54, and below the 200-day MA of 6.01, indicating a bearish trend. The MACD of -0.29 indicates Negative momentum. The RSI at 39.30 is Neutral, neither overbought nor oversold. The STOCH value of 36.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OSG.
Octave Specialty Group Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% |
* Financial Sector Average
Performance Comparison
Octave Specialty Group Corporate Events
Executive/Board ChangesShareholder Meetings
Octave Specialty Group Shareholders Back Governance and Pay Plans
Positive
May 29, 2026
At its annual meeting of stockholders held on May 28, 2026, Octave Specialty Group, Inc. reported that approximately 81% of its outstanding common shares were represented, underscoring strong investor engagement in the company’s governance. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.